5:40 PM
 | 
Jun 13, 2014
 |  BC Extra  |  Clinical News

TG Therapeutics gains on ublituximab data

TG Therapeutics Inc. (NASDAQ:TGTX) said IV ublituximab ( TG-1101) plus once-daily oral Imbruvica ibrutinib led to an overall response rate (ORR) of 90% in 10 evaluable patients in the open-label Phase II UTX-IB-104 trial to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >